|Earth Science Tech, Inc. (ETST) Sees DEA Decision to Reschedule CBD Opening Doors for Development of Treatments for Multiple Illnesses|
- U.S. Drug Enforcement Agency’s (DEA) decision to remove certain CBD products from its Schedule 1 list of controlled substances will make CBD clinical studies easier to plan
- ETST’s pipeline includes CBD-based pharmaceutical formulas; company expects its pure hemp oil and new formulas to eventually be sold worldwide
- ETST will be a licensed distributor and plans to work closely with pharmacists and researchers to serve this market; it plans to launch two CBD nutraceutical formulas
Earth Science Tech, Inc.’s (OTCQB: ETST) anticipation that its pure hemp oil and new formulas will eventually be sold globally and that it will be a licensed distributor and will work closely with pharmacists and researchers to serve the cannabis market has been strengthened by the DEA’s recent decision on CBD (http://nnw.fm/HXaY7).
The DEA decided to remove some CBD products from its Schedule 1 list of controlled substances. It voted to reclassify FDA-approved drugs that contain cannabis-derived CBD and contain less than 0.1% tetrahydrocannabinol (THC) as Schedule V, the lowest restriction classification.
ETST sees this ruling as an opportunity. In a news release, Dr. Michel Aubé, CEO and chief science officer of ETST, said, “In 2018, we have a much deeper understanding of cannabinoids, cannabinoid-receptors, and the endocannabinoid system than we did decades ago when CBD was classified as a schedule 1 drug. We are pleased to see that the DEA has shifted its stance amid conclusive evidence that CBD is not addictive but has both anti-psychotic properties and the opposite effect of THC.”
ETST is a biotech company based in Doral, Florida, marketing and developing CBD products for the pharmaceutical and nutraceutical fields. The company is focused on the cannabidiol, pharmaceutical and nutraceutical sectors, as well as the development, through subsidiaries, of medical devices and research. ETST’s goal is to become a world leader in the CBD space.
ETST has announced that it will soon launch two CBD-based nutraceutical formulas under a provisory patent. These include a neuron protector and a breast protector. The company is also developing a new brand for these formula patents.
The company said that the Quebec Agrifood Innovation Center (QAIC) is completing the standardization of the formulas. By the end of October, TransBiotech is expected to conduct in vitro testing of the biological activities of the formula, comparing the level of protection offered by ETST’s hemp oil alone versus its hemp oil with other natural ingredients.
Nickolas S. Tabraue, president and director of ETST, added, “The results obtained from TransBiotech will help us understand the mechanism of action of CBD and will open the doors for the research needed to develop revolutionary CBD-based pharmaceutical drugs.”
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. ETST also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer